ALN-5288
/ Alnylam, Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 30, 2026
ALN-5288, An Investigational RNA Interference Therapeutic Targeting MAPT In Phase 1 Development For Alzheimer's Disease
(AAIC 2026)
- No abstract available
P1 data • Alzheimer's Disease • CNS Disorders • MAPT
November 14, 2025
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
(clinicaltrials.gov)
- P1 | N=50 | Recruiting | Sponsor: Alnylam Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders
October 16, 2025
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Alnylam Pharmaceuticals
New P1 trial • Alzheimer's Disease • CNS Disorders
1 to 3
Of
3
Go to page
1